Fri, Jul 11, 2014, 10:17 AM EDT - U.S. Markets close in 5 hrs 43 mins

Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

robchadwick 2 posts  |  Last Activity: Jun 16, 2014 6:34 PM Member since: Feb 4, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • UBS had a fairly intelligent coverage statement on SNSS with a Buy Rating and a price target of $14. Their analysis was pretty high level, but on point. By comparison The Street's downgrade of SNSS was an automated downgrade with no information about their pipeline and solely focused on revenue - totally inappropriate for pharmaceutical company that has not yet brought their product to market.

    UBS Coverage of SNSS:
    UBS initiated coverage on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) with a Buy rating and a price target of $14.00.

    Analyst Andrew Peters said, "Key points from our analysis: [1] SNSS provides an exceptionally high risk/reward ahead of the ph3 VALOR read-out in 2H14. We are positively biased on the trial and see asymmetric upside on favorable data. [2] By some metrics, the current valuation implies

    Sentiment: Hold

  • robchadwick robchadwick May 12, 2014 4:29 PM Flag

    Totally uninformed automatically generated downgrade. Doesn't address any of the fundamentals of the company's ongoing research or where they are at in the pipeline.

    Plus: the drug seems to work with a substantially higher survivability rate with vosaroxin + cytarabine than cytarabine alone.

    Minus: This is looking like a combination treatment, not a solo treatment

    Plus: The drug shows promise for Myleodysplastic Syndrome (MDS) as well as AML - larger market.

    Minus: The results of the studies have again been pushed out.

    Plus: The results of the studies have been pushed out because of higher/longer survival rate than anticipated

    Current income is meaningless when looking at this stock & The Street does a disservice by providing upgrades/downgrades that don't reflect the true fundamentals of pharmaceutical companies that do not have a drug on the market.

    People were hoping the drug would be brought to market by now, but the fact that the studies have been delayed due to positive survival rate is a good thing for long term investors. Short term investors are getting flushed out or moving to short the stock.

    Balance sheet and cash flow are relatively healthy, so I think further dilution would happen at a time when the drug is ready to hit the market and the valuation of the company will be much higher.

    I think this stock is going to bounce around a lot over the next few months. If I didn't have so much invested in this stock, I'd buy more on the dips. AML & MDS are nasty and mainstay maintenance treatments like Aeronesp, Procrit, etc have had major issues with heavy duty side effects coming to light over the past few years.

    Sentiment: Hold

SNSS
6.14-0.01(-0.16%)10:15 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.